Background: Asymmetric allele expression typically indicates functional and/or structural features associated with the underlying genetic variants. When integrated, RNA and DNA allele frequencies can reveal patterns characteristic of a wide-range of biological traits, including ploidy changes, genome admixture, allele-specific expression and gene-dosage transcriptional response.
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Introduction RNA and DNA carry and present genetic variation in related yet distinct manners; the differences being informative of functional and structural traits. In diploid organisms, an important measure of genetic variation is the allele frequency, which can be measured from both genome (DNA) and transcriptome (RNA) sequencing data (encoded and expressed allele frequency, respectively). Differential DNA-RNA allele frequencies are associated with a variety of biological processes, such as genome admixture or allele-specific transcriptional regulation (Ferreira, et al., 2016; Ha, et al., 2012; Han, et al., 2015; Movassagh, et al., 2016; Shah, et al., 2012) .
Most of the RNA-DNA allele comparisons from sequencing have been approached at nucleotide level, where it has proven to be highly informative for determining the alleles' functionality (Ferreira, et al., 2016; Ha, et al., 2012; Han, et al., 2015; Macaulay, et al., 2016; Morin, et al., 2013; Movassagh, et al., 2016; Reuter, et al., 2016; Shah, et al., 2012; Shi, et al., 2016; Shlien, et al., 2016; Yang, et al., 2016) . Comparatively, integration of allele signals at the molecular level, as derived from linear DNA and RNA carriers, is less explored due to challenges presented by short sequencing length. The different molecular nature of RNA and DNA also leads to limited compatibility of the sequencing output.
Herein, we address some of the above challenges by employing a mathematical model to assess differences between RNA-and DNA-variant allele frequencies (VAF) at single nucleotide variant (SNV) positions in the genome. To do that, we introduce GeTallele: a toolbox that provides a suit of functions for integrative analysis and visualization of Genome (VAFDNA) and Transcriptome (VAFRNA) allele frequencies along genes and chromosomes. Using VAF, GeTallele infers possible copy number alterations (CNAs), and, at Analysis of the VAFRNA and VAFDNA in the GeTallele is based on comparing probability of observing a given VAF value at various positions of interest. Estimation of the variant allele probability (vPR) is implemented using a data-driven mathematical model of distribution of the VAF values and is the core functionality of the GeTallele.
Estimation of variant probability vpr

Variant probability
GetAllele aggregates frequency counts of a VAF sample into variant probability, vPR -probability of observing a variant allele. The vPR is a single informative value indicative of copy number variation. The vPR is a parameter that describes the genomic event that through the sequencing process was transformed into a specific distribution of VAF values found in the signal. For example, in VAFDNA from a diploid genome, variant probability vPR=0.5 (meaning that both alleles are equally probable) corresponds to a true allelic ratio of 1:1 for heterozygote sites. For heterozygote sites in the DNA from diploid monoclonal sample, the corresponding tumour VAFDNA is expected to have the following interpretations: vPR=1 or vPR=0 corresponds to a monoallelic status resulting from a deletion, and vPR=0.8 (or 0.2), 0.75 (or 0.25), 0.67 (or 0.33) correspond to allelespecific tetra-, tri-, and duplication of the variant-bearing allele, respectively.
The vPR of the VAFRNA is interpreted as follows. In positions corresponding to DNA heterozygote sites, alleles not preferentially targeted by regulatory traits are expected to have expression rates with variant probability vPR=0.5, which (by default) scale with the DNA allele distribution. Differences between VAFDNA and VAFRNA values are observed in special cases of transcriptional regulation where one of the alleles is preferentially transcribed over the other. In the absence of allele-preferential transcription, VAFDNA and VAFRNA are anticipated to have similar vPR across both diploid (normal) and aneuploid (affected by CNAs) genomic regions. Consequently, VAFDNA and VAFRNA are expected to synchronously switch between allelic patterns along the chromosomes, with the switches indicating break points of DNA deletions or amplifications.
Since we observed that DNA and RNA signals have different distributions of total reads and also that the distributions of total reads vary between participants, the model VAF distributions are generated individually for each sequencing signal and each participant.
To estimate vPR in the signals, GeTallele first generates model VAF distributions and then uses the earth mover's distance (EMD) (Kantorovich and Rubinstein, 1958; Levina and Bickel, 2001) to fit them to the data. To generate a model VAF distribution with a given variant probability, vPR, GeTallele, bootstraps 10000 values of the total reads (sum of the variant and reference reads; nVAR + nREF) from the analysed signal in the dataset. It then uses binomial pseudorandom number generator to get number of successes for given number of total reads and a given value of vPR (implemented in the Matlab function binornd). The vPR is the probability of success and generated number of successes is interpreted as an nVAR. Since the model vPR can take any value, it can correspond to a single genomic event as well as any combination of genomic events in any mixture of normal and tumour populations (See section 2.1.3).
The analysis presented in the paper uses 51 model VAF distributions with vPR values that vary from 0.5 to 1 with step (increment of) 0.01. The model VAF distributions are parametrized using only vPR ≥ 0.5, however, to generate them we use vPR and its symmetric counterpart 1-vPR. The process of generating model VAF distributions and examples of model and real VAF distributions with different values of vPR are illustrated in Fig.  3 . Fig. 3 . Model and real VAF distributions. A Description of the model used to generate model VAF distributions, Bin(n,p) stands for binomial distribution with parameters n (number of trials) and p (probability of success). B -F Model VAF distributions for different values of vPR. Panels B and F show additionally distributions of VAFTEX for the two windows shown in Figure 1D .
vPR estimation
Earth mover's distance (EMD) is a metric for quantifying differences between probability distributions (Kantorovich and Rubinstein, 1958; Levina and Bickel, 2001 ) and in the case of univariate distributions it can be computed as:
.
Here, PDF1 and PDF2 are two probability density functions and CDF1 and CDF2 are their respective cumulative distribution functions. Z is the support of the PDFs (i.e. set of all the possible values of the random variables described by them). Because VAFs are defined as simple fractions with values between 0 and 1, their support is given by a Farey sequence (Hardy, et al., 2008) of order n; n is the highest denominator in the sequence. For example, Farey sequence of order 2 is 0, 1/2, 1 and Farey sequence of order 3 is 0, 1/3, 1/2, 2/3, 1. GeTallele uses a Farey sequence of order 1000 as the support Z for all computations involving EMD. To estimate vPR, GeTallele computes EMD between the distribution of the VAF values of each signal in the window and the 51 model VAF distributions (i.e. observed vs modelled VAF), the estimate is given by the vPR of the model VAF distribution that is closest to the VAF distribution in the window. Examples of VAF distributions with fitted model VAF distributions are shown in Figure 3A and D. The dependence of the confidence intervals of the estimation on the number of VAF values in a window is illustrated in Fig. 4 , which clearly demonstrates that the larger the number of VAFs in the chosen window the higher the accuracy of the estimate. Fig. 4 . Confidence intervals for artificial samples with different numbers of VAFs. Each confidence interval is based on estimation of vPR in 1000 randomly generated samples with a fixed vPR (True value). Light grey bar is 95% confidence interval (950 samples lay within this interval), dark grey bar is 50% confidence interval (500 samples lay within this interval), red dot is median value.
vPR values in mixtures of normal and tumour populations
Since the vPR can take any value between 0.5 and 1 it can correspond to a single genomic event as well as any combination of genomic events in any mixture of normal and tumour populations. A mixture vPR value that corresponds to a combination of genomic events can be computed using the following expression: Where eVAR and eREF are the multiplicities of variant and reference alleles and pPL is a proportion of one of the populations. For heterozygote sites eVAR=1 and eREF=1, for deletions eVAR=0 or eREF=0, for du-, tri-and tetraplications eVAR or eREF can be equal to 2, 3 or 4, respectively. The sum of proportions pPL over the populations is equal 1. For example, for a mixture of 1 normal (N, pN=0.44) and 2 tumour populations (T1, pT1=0.39 and T2, pT2=0.17), T1 with deletion and T2 with deletion the mixture vPR value can be computed as follows: By comparing the vPR values estimated from data with possible mixture vPR values we propose to estimate sample purity and its clonal composition. To this end, we first generate a full set of proportions of all the population in the mixture with step (increment of) 0.01 and compute all the possible vPR values that each of the mixtures could produce. For step 0.01: two populations (1 tumour) give 99 proportions, three populations (2 tumours) give 4851 proportions, four populations (3 tumours) give 156849 proportions. The matrices with mixture vPR values for each proportion, vary from 2x2, for two populations with deletions, to 35x35 for four populations with all events up to tetraplications. Then, we run an exhaustive approximate search over all the matrices with mixture vPR values over all the proportions. The search is approximate because the estimated vPR values have limited accuracy and because we consider only discrete values of proportions. In the analysis we define a match between estimated and mixture vPR values if they differ <0.009. The search returns a large number of admissible mixtures that could produce the estimated vPR values. This process is illustrated in Fig.  5 .
To represent the admissible mixtures graphically we use ternary plots. Ternary plot allows to illustrate composition of three components using just two dimensions. The composition, represented by ratios of the three components which sum to a constant, is depicted as point inside or on the edge of an equilateral triangle. If the point is on the edges, the composition has only two components. To facilitate interpretation of the ternary plots, we also plot the grid lines that are parallel to the sides of the triangle. These gridlines indicate the directions of constant ratios of the components. Along such direction the ratio of one of the components is fixed and only the other two ratios vary. Examples of visualisation of admissible mixtures on ternary plots are shown in Figs. 5 and 6. To uncover mixtures that could produce the three estimated vPR values we perform an exhaustive approximate search of all the possible vPR values produced by any mixture of the populations with a given set of genetic events. In each case we generate a full set of proportions with a given step (e.g. 0.01) and compute all the possible vPR values that such a mixture could produce. In the illustrated cases: 2 populations (1 tumour) could produce the estimated vPR values through a deletion (estimated vPR=0.62 and vPR=0.63 ) and via deletion of one allele and duplication of another (estimated vPR=0.69); 3 populations (2 tumours) could produce the estimated vPR values through a deletion in one of the tumour populations (estimated vPR=0.62 and vPR=0.63) and via deletion in both of the tumour populations (estimated vPR=0.69). The 2 populations case admits a single mixture and the 3 populations allow 9 mixtures with similar compositions. The admissible mixtures are depicted on the ternary plots, red circle indicates solution corresponding to the presented matrix. We exclude mixture vPR values that result from deletion of both the variant and reference alleles (empty fields in the matrices).
To facilitate analysis of the admissible mixtures returned by the search procedure we introduce mixture complexity. Mixture complexity is a measure that increases with number of populations as well as with variety of genetic events. From the simplest mixture of 1 normal and 1 tumour population in which only deletions are possible to a model with 1 normal and multiple tumour populations where each can have deletions, and any level of multiplications. In practice, we set the limit at 3 tumour populations and tetraplications. Mixture complexity helps to group and visualise admissible mixtures. Mixtures with higher complexity allow more possible vPR values, meaning that it is easier to find the match with the estimated vPR values and the number of admissible mixtures increases (see Figure 6) . We, further, observe that proportion of normal population, pN, increases with a number of clonal tumour populations included in the model mixture and that, generally, pN stays constant with increasing variety of genetic events, for a fixed number of clonal tumour populations. 
Analysis of RNA-DNA relationships
GetAllele is readily applicable to assess RNA-DNA relationships between normal and tumour sequencing signals derived from the same sample/individual (matched datasets). As a proof of concept, we assessed matched normal and tumour exome and transcriptome sequencing data of 72 breast carcinoma (BRCA) datasets with pre-assessed copy-number and genome admixture estimation acquired through TCGA (Supplementary Table 1 ). For these datasets, purity and genome admixture has been assessed using at least three of the following five approaches: ESTIMATE, ABSOLUTE, LUMP, IHC, and the Consensus Purity Estimation (CPE) (Aran, et al., 2015; Carter, et al., 2012; Katkovnik, et al., 2002; Pagès, et al., 2010; Yoshihara, et al., 2013; Zheng, et al., 2014) . In addition, on the same datasets we applied THetA -a popular tool for assessing CNA and admixture from sequencing data (Oesper, et al., 2013; Oesper, et al., 2014) .
Segmentation results
Segmentation of the data, based on the tumour exome signal, resulted in 2697 windows across the 72 datasets. We excluded from further analysis 294 windows where either tumour exome or transcriptome had vPR>=0.58 but their VAF distribution could not be differentiated from the model VAF distributions with vPR=0.5 (p>1e-5, Kolmogorov Smirnov test, equivalent to Bonferroni FWER correction for 100000 comparisons). The 294 excluded windows correspond to 4% of the data in terms of number of base pairs in the windows and 4% of all the available data points; i.e. they are short and contain only few VAF values. In the remaining 2403 windows, we systematically examined the similarity between corresponding VAFTEX (tumour exome), VAFTTR (tumour transcriptome) and CNA. We obtained several distinct patterns of coordinated RNA-DNA allelic behaviour as well as correlations with CNA data.
In 60% of all analysed windows the distributions of VAFTEX and VAFTTR were statistically concordant (had p>1e-5, Kolmogorov Smirnov test), and in 40% they were statistically discordant (p<1e-5, Kolmogorov Smirnov test). In 2 windows VAFTEX and VAFTTR had the same vPR but had statistically different distributions (p<1e-5, Kolmogorov Smirnov test), we consider such windows as concordant; Kolmogorov-Smirnov test is very sensitive for differences between distributions, vPR fitting is more robust. In the vast majority of the discordant windows vPR of the VAFTTR, vPR,TTR, was higher than vPR of the VAFTEX, vPR,TEX, (only in 21 out of 959 discordant windows vPR,TTR was lower than vPR,TEX).
Concurrence of segmentation based on DNA and RNA
We next analysed the concurrence between windows resulting from independent segmentations of the dataset based on the tumour exome and transcriptome signals in the datasets (2697 and 3605 windows, respectively, across all the samples). We first assessed chromosome-wise alignment of the start and end points of the windows. In 45% of the chromosomes both VAFTEX and VAFTTR signals produce a single window that contains the whole chromosome. In 33% of chromosomes both signals produced multiple windows. These windows are well aligned, with 90% of the break-points within 7% difference in terms of the number of data points in the chromosome (Q50=0.02%, Q75=2% of data points in the chromosome). The probability of observing such an alignment by chance is smaller than p=1e-5 (100,000 bootstrap samples with breaking points assigned randomly in all the individual chromosomes where both signals produced multiple windows). In 22% of the chromosome windows based on VAFTEX and VAFTTR the signals were positionally discordantone signal produced a single window containing whole chromosome while the other produced multiple windows.
To compare the vPR values in the 55% of chromosomes where at least one signal produced more than one window, we computed chromosome-wise mean absolute error (MAE) between the vPR in two sets of windows. To account for different start and end points of the windows we interpolated the vPR values (nearest neighbour interpolation) at each data point in the chromosome. We separately compared the vPR,TEX and vPR,TTR values. The alignment in terms of MAE is very good, vPR,TEX agreed perfectly in 11% of the chromosomes and had the percentiles of MAE equal to Q50= 0.012, Q75= 0.022 and Q97.5= 0.047, while vPR,TTR agreed perfectly in 8% but had slightly higher percentiles of MAE Q50= 0.019, Q75= 0.034 and Q97.5= 0.07. vPR,TEX and vPR,TTR values had MAE=0 simultaneously in 4% of the chromosomes. Probability of observing such values of MAE by chance is smaller than p=1e-3 (1000 random assignments of vPR,TEX and vPR,TTR values to windows in the 873 chromosomes where at least one signal had more than one window). It is noteworthy that MAE Q97.5<0.07 is comparable with the confidence interval of single vPR estimate based on 50 VAF values. In other words, both signals in a sample (Tex and Ttr) give very similar results in terms of windows' segmentation and estimated values of the vPR. Albeit, segmentation of VAFTTR generates a higher number of windows. Figure 7 shows examples of concurrence between windows based on VAFTEX and VAFTTR signals in a positionally concordant chromosome (both signals produced multiple windows). 
Correlation between vPR and CNA
Finally, we assess the correlations between vPR and CNA in the individual datasets. We separately computed correlations for deletions and amplifications. In order to separate deletions and amplifications, for each data set we found CNAMIN, value of the CNA in the range -0.3 to 0.3 that had the smallest corresponding vPR,TEX. To account for observed variability of the CNA values near the CNAMIN, we set the threshold for amplifications to CNAA = CNAMIN-0.05, and for deletions we set it to CNAD = CNAMIN+0.05.
For VAFTEX we observed significant correlations with negative trend between vPR,TEX and CNA ≤ CNAD in 57 datasets and with positive trend between vPR,TEX and CNA ≥ CNAA in 39 datasets (pFDR<0.05, Pearson's correlation with Benjamini Hochberg multiple comparison correction for 72 samples). For VAFTTR we observed significant correlations with negative trend between vPR,TTR and CNA ≤ CNAD in 62 datasets and with positive trend between vPR,TTR and CNA ≥ CNAA in 33 datasets (pFDR<0.05, Pearson correlation with Benjamini Hochberg correction). These correlations indicate that although vPR,TEX as well as vPR,TTR values capture information contained in CNA, they do not differentiate between positive and negative values of the CNA. 
vPR based purity estimation
To demonstrate a practical application of estimating the admissible mixtures by means of comparing the estimated vPR,TEX values with the mixture vPR values we next use them to estimate purity of the samples. To this end we compared the vPR based purity (VBP) estimates with ESTIMATE, ABSOLUTE, LUMP, IHC, and the Consensus Purity Estimation (CPE) (Aran, et al., 2015; Carter, et al., 2012; Katkovnik, et al., 2002; Pagès, et al., 2010; Yoshihara, et al., 2013; Zheng, et al., 2014) .
To obtain the VBP estimate we used vPR,TEX values. We, first, selected the vPR,TEX values that: 1. are estimated with high confidence, i.e. are based on at least 50 data points; 2. are most likely heterozygous in normal exome, i.e., have a corresponding vPR value in normal exome vPR,NEX <0.59; 3. most likely have vPR,TEX > 0.5, i.e., their p-value for comparison with vPR,TEX = 0.5 is very small p<1e-5 (Kolmogorov-Smirnov test). Next, we used the selected vPR,TEX values to find all admissible mixtures (with 1 to 3 tumour populations and allowing for all events, from deletions to tetraplications). To estimate the VBP, out of all the admissible mixtures we chose these with lowest mixture complexity and among these mixtures we take one with the highest pN (proportion of the normal population). The VBP, percentage of tumour populations in the sample, is then given as 1-pN. Such approach provides rather conservative estimates of VBP (the smallest 1-pN). However, GetAllele can be extended to offer alternative methods of employing the admissible mixtures to estimate VBP. Development, analysis and comparison of alternative VBP estimation methods is beyond scope of the current paper. Figure 9A shows violin plots of all considered 1-pN values and (x) indicates the smallest value taken as a VBP estimate. In two of the datasets we could not estimate the purity due to lack of suitable vPR,TEX values. The VBP estimates shows the best agreement with ABSOLUTE method (r=0.76, p<3.4e-14, Pearson's correlation, Fig. 9B2 ). We suppose that this is because the ABSOLUTE method is based on copy number distributions, and our analysis (Section 2.2.3) revealed high correlations between the CNAs and vPR values. Similarly to the ABSOLUTE method, VBP estimates are generally lower than the other purity estimates (ESTIMATE, LUMP, IHC, CPE); see Fig. 9B1-B5 .
The approach presented in this section differs from other methods for inferring genomic mixture composition (e.g. SciClone (Miller, et al., 2014) , or PyClone (Roth, et al., 2014) ) in that it is based on changes of the alleles multiplicity estimated along continuous multi-SNV genomic regions. The vPR values used to estimate admissible mixtures are based on windows with at least 50 VAF values which extend over millions of base pairs. In this way, the presented method is complementary to the SciClone and PyClone methods that use VAFs of somatic mutations. 
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Discussion Potential for integrative analysis of RNA and DNA sequence data is facilitated by the growing availability of RNA and DNA sequencing datasets and by the technological advances now enabling simultaneous RNA and DNA sequencing from the same source (Macaulay, et al., 2016; Reuter, et al., 2016; . However, integrative RNA and DNA analyses are challenged by limited compatibility between RNA and DNA datasets and high technical variance of the sequencing-produced signals. Our approach -GeTalleleaddresses the compatibility by restricting the analyses to confidently co-covered DNA and RNA regions, and the high variability -through quantification of differences between the DNA and RNA signals.
In contrast to other methods based on statistical modelling, GeTallele is based on a mechanistic model of VAF distributions that depends on the distribution of total reads (extracted from data) and the vPR parameter. The brute-force simplicity and transparency of the presented methodology is one of its biggest advantages.
Additionally, in contrast to other methods, to analyse sequencing data GeTallele uses data segments that include multiple adjacent SNVs. Finally, GeTallele offers a unified pipeline to evaluate and visualise DNA-RNA whereas many of the other methods cited herein are used in conjunction with each other to achieve a similar result.
Using GeTallele, we detected several relationships between DNA-RNA allele frequencies and biological processes. First, in chromosomes affected by deletions and amplifications, VAFRNA and VAFDNA showed highly concordant breakpoint calls. This indicates that VAFRNA alone can serve as preliminary indicator for deletions and amplifications, which can facilitate the applications of RNA-sequencing analysis on the large and constantly growing collections of transcriptome sequencing data. Second, we showcased that vPR,TEX can be used to estimate sample composition (in terms of proportions of normal and tumour populations) and as a result its purity. Once the mixture composition is decided by the user, GeTallele allow to further interrogate genetic events in each population at a specific data segment.
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Conclusions Based on our results, variant probability vPR can serve as a dependable indicator to assess gene and chromosomal allele asymmetries and to aid calls of genomic events in matched sequencing RNA and DNA datasets. Methods for estimating and analysing vPR values are implemented in a GeTallele toolbox. GeTallele provides a singular suit of functions for integrative analysis, statistical assessment and visualization of the observed patterns at desired resolution, including chromosome, gene, or custom genome region.
Methods
Samples
The GeTallele was developed using sequencing datasets from paired normal and tumour tissue obtained from 72 female patients with breast invasive carcinoma (BRCA) from The Cancer Genome Atlas (TCGA). Each of the 72 datasets contains four matched sequencing datasets: normal exome (Nex), normal transcriptome (Ntr), tumour exome (Tex), and tumour transcriptome (Ttr). In addition, we required each tumour sample to have at least three of the following five purity estimates -Estimate, Absolute, LUMP, IHC, and the consensus purity estimate (CPE), (Supplementary Table 1 ). Finally, each sample was required to have CNA estimation (genomic segment means based on Genome-Wide-SNPv6 hybridization array) (Aran, et al., 2015; Carter, et al., 2012; Katkovnik, et al., 2002; Pagès, et al., 2010; Yoshihara, et al., 2013; Zheng, et al., 2014) .
Data processing
All datasets were generated through paired-end sequencing on an Illumina HiSeq platform. The human genome reference (hg38)-aligned sequencing reads (Binary Alignment Maps, .bams) were downloaded from the Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/) and processed downstream through an in-house pipeline. After variant call (Li, 2011) , the RNA and DNA alignments, together with the variant lists were processed through the read count module of the package RNA2DNAlign (Movassagh, et al., 2016) , to produce variant and reference sequencing read counts for all the variant positions in all four sequencing signals (normal exome, normal transcriptome, tumour exome and tumour transcriptome). Selected read count assessments were visually examined using Integrative Genomics Viewer (Thorvaldsdóttir, et al., 2013) .
Data segmentation
To analyse variant allele frequencies (VAF) at genome-wide level, GeTallele first divides the VAF dataset into a set of non-overlapping windows along the chromosomes. Segmentation of the dataset into windows is based on a sequencing signal chosen out of all the available datasets in the aggregated aligned VAF dataset (one out of four in the presented analysis).
To partition the data into the windows GeTallele uses a parametric global method, which detects the breakpoints in the signals using its mean, as implemented in the Matlab function findchangepts (Killick, et al., 2012; Lavielle, 2005) or in R (Killick and Eckley, 2014) . In each window, the VAF values of the chosen signal have a mean that is different from the mean in the adjacent windows. Sensitivity of breakpoint detection can be controlled using parameter MinThreshold, in the presented analysis it was set to 0.2. For segmentation and analysis (without loss of generality) we transform all the original VAF values to VAF=|VAF-0.5|+0.5.
Statistics
To test statistical significance, GeTallele uses parametric and non-parametric methods and statistical tests (Corder and Foreman, 2014; Hollander, et al., 2013 To account for multiple comparisons, we set the probability for rejecting the null hypothesis at p<1e-5, which corresponds to Bonferroni (Dunn, 1961) family-wise error rate (FWER) correction against 100000 comparisons. We use a fixed value, rather than other approaches, to ensure better consistency and reproducibility of the results. Alternatively, we apply Benjamini and Hochberg (Benjamini and Hochberg, 1995) false discovery rate (FDR) correction with a probability of accepting false positive results pFDR<0.05. We specify the method used in the text when reporting the results. ML data acquisition; PS data analysis; PS, ML, PR, LFS, KTA, AH interpretation of data; PS the creation of new software used in the work; PS, ML, PR, LFS, KTA, AH have drafted the work or substantively revised it; all authors approved the submitted version. All authors agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.
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• Acknowledgements: Not applicable 1 001_Nex_BRCA_TCGA-BH-A1FC-11A_413b80f6-f6cf-4992-804a-f045e38cbe6f 0.7615 0.49 0.6693 0.9 0.6517 001_Ntr_BRCA_TCGA-BH-A1FC-11A_086db136-f3f2-42fa-aca1-63847de6ccb9 001_Tex_BRCA_TCGA-BH-A1FC-01A_1a2187a6-aea8-4096-8c3f-208a8467cd5a 001_Ttr_BRCA_TCGA-BH-A1FC-01A_b5e2f568-e6fc-4192-a3ab-da956e5bfa4c 2 002_Nex_BRCA_TCGA-BH-A0B5-11A_c724807c-d80d-4582-8238-8339397b6aec 0.7539 0.5 0.8944 0.575 0.6566 002_Ntr_BRCA_TCGA-BH-A0B5-11A_f478930d-216a-40ec-b434-bfc3a7b2f62b 002_Tex_BRCA_TCGA-BH-A0B5-01A_803de3d6-895f-4ad1-a86c-6f72d6ea8430 002_Ttr_BRCA_TCGA-BH-A0B5-01A_37175dfe-e34e-4f97-88b1-c0ba4bd5d093 3 003_Nex_BRCA_TCGA-BH-A0BJ-11A_a9988fbb-090a-4363-bf73-7505e1710623 0.7386 0.37 0.8453 0.7 0.7458 003_Ntr_BRCA_TCGA-BH-A0BJ-11A_2ced85bc-852a-4056-ad11-2e88ec6d2d82 003_Tex_BRCA_TCGA-BH-A0BJ-01A_58ec1111-c932-49ea-9327-1c64dfc2afa6 003_Ttr_BRCA_TCGA-BH-A0BJ-01A_73442f2d-3453-42ee-b57a-86871e2e2fd9 4 004_Nex_BRCA_TCGA-E2-A158-11A_58fe3067-8198-486e-b0b2-286dc4451c39 0.9534 NaN NaN 0.8 0.7799 004_Ntr_BRCA_TCGA-E2-A158-11A_323eb80d-71e2-4223-b471-a83ee42e6e08 004_Tex_BRCA_TCGA-E2-A158-01A_0329fa7e-d768-4bbe-940e-36f0b9829d7c 004_Ttr_BRCA_TCGA-E2-A158-01A_9d31f395-85e7-4ad8-95a3-0cc796c4b81d 5 005_Nex_BRCA_TCGA-A7-A13E-11A_bd7e6f8f-7213-4ded-a8ca-3c73c7b8d918 0.909 0.83 0.9772 0.85 0.9184 005_Ntr_BRCA_TCGA-A7-A13E-11A_99c08ce4-6526-4982-9bc7-b9c07972bcdb 005_Tex_BRCA_TCGA-A7-A13E-01A_28b8b84b-ca69-4c6a-860c-989777b18d32 005_Ttr_BRCA_TCGA-A7-A13E-01A_148d5aec-6026-46b5-b40c-38a1198175ab 6 006_Nex_BRCA_TCGA-BH-A208-11A_645b786f-1942-4cce-973b-4a75956265f5 0.5951 0.31 0.6877 0.6 0.5642 006_Ntr_BRCA_TCGA-BH-A208-11A_a6dd96f4-f194-4c8d-8757-9e8b35465a9f 006_Tex_BRCA_TCGA-BH-A208-01A_5bdbd7db-ced4-4446-9069-c44c9c1f0ae0 006_Ttr_BRCA_TCGA-BH-A208-01A_794bcf95-8e66-4f91-a49c-ab10defe73c5 7 007_Nex_BRCA_TCGA-BH-A1FU-11A_db7e821b-a2b6-40e1-9fbc-c72231b703a4 0.6835 0.25 0.667 0.6 0.6121 007_Ntr_BRCA_TCGA-BH-A1FU-11A_c051b92b-8e11-4623-b11b-3a0d52710663 007_Tex_BRCA_TCGA-BH-A1FU-01A_cb37bb7f-8fb6-432a-a58a-f8178d5baa64 007_Ttr_BRCA_TCGA-BH-A1FU-01A_7ea95c3a-b1a6-4658-b4c2-f35f3f48394e 8 008_Nex_BRCA_TCGA-BH-A0AY-11A_2ecc0325-3973-48b3-b53b-bb52aea5a9bc 0.6376 0.42 NaN 0.7 0.5612 008_Ntr_BRCA_TCGA-BH-A0AY-11A_1b2877ac-94a0-464c-b58b-9ce2f16aff37 008_Tex_BRCA_TCGA-BH-A0AY-01A_357ccb95-03e5-49f6-ab18-38d4c8d4d820 008_Ttr_BRCA_TCGA-BH-A0AY-01A_a19a60e7-e5ca-4f66-96fe-c9add702177d 9 009_Nex_BRCA_TCGA-BH-A18U-11A_bf3d62cb-f3a6-45d6-b9c3-416e58f1d319 0.7949 0.68 NaN 0.75 0.8077 009_Ntr_BRCA_TCGA-BH-A18U-11A_9d4c1d7e-dd77-41d1-b1df-144e7afb2141 009_Tex_BRCA_TCGA-BH-A18U-01A_a80933e5-3b07-41dc-b7f0-499d63c071a9 009_Ttr_BRCA_TCGA-BH-A18U-01A_ff89e0d9-7e6c-4b6b-a1c3-f800aaa414a1 10 010_Nex_BRCA_TCGA-AC-A2FF-11A_714e11fb-be71-4bbd-9327-457883a07ef0 0.5705 NaN 0.6868 0.8 0.6667 010_Ntr_BRCA_TCGA-AC-A2FF-11A_4d32c4fa-959e-41cf-b837-104290bab9fa 010_Tex_BRCA_TCGA-AC-A2FF-01A_5c6fe1fc-839c-422a-89e7-4a54dcfad6c2 010_Ttr_BRCA_TCGA-AC-A2FF-01A_37bf962c-b180-4cc2-8e0b-fde78b4f99f4 11 011_Nex_BRCA_TCGA-BH-A0BQ-11A_a5bdd116-8c1b-4787-be01-4c0f96709cc5 0.6814 0.4 NaN 0.5 0.5779 011_Ntr_BRCA_TCGA-BH-A0BQ-11A_45e17d22-fbed-418b-97fc-7104e1deeac1 011_Tex_BRCA_TCGA-BH-A0BQ-01A_27138381-1865-4a6a-bd70-58725c92cb49 011_Ttr_BRCA_TCGA-BH-A0BQ-01A_8879454d-b803-40b6-b3d7-fbc295de9df6 12 012_Nex_BRCA_TCGA-BH-A0BA-11A_9dbc7f19-30bd-48fd-8d5a-ca67dc26c5b1 0.7944 0.48 0.8945 0.87 0.7278 012_Ntr_BRCA_TCGA-BH-A0BA-11A_2cc17895-0a6e-4703-8164-7034f5c2e1a8 012_Tex_BRCA_TCGA-BH-A0BA-01A_b4c0df66-54c1-4bbf-9a3c-d2fd28d5bb4b 012_Ttr_BRCA_TCGA-BH-A0BA-01A_a9f9701c-6b4b-48ed-af83-94804fb098a8 13 013_Nex_BRCA_TCGA-BH-A0B8-11A_ef67ace2-01d6-4e8b-92c7-7c4e1e5ca327 0.8571 0.87 0.9827 0.85 0.9342 013_Ntr_BRCA_TCGA-BH-A0B8-11A_3a833d6d-75c7-4381-8cef-699c633b64e6 013_Tex_BRCA_TCGA-BH-A0B8-01A_54972439-f9da-497d-a605-24e9670021ad 013_Ttr_BRCA_TCGA-BH-A0B8-01A_9c7776d0-33df-4bd7-a720-807c650fdbc5 14 014_Nex_BRCA_TCGA-BH-A0AU-11A_15483d36-ad24-4771-a991-8a8435effc6a 0.765 0.46 0.8525 0.775 0.652 014_Ntr_BRCA_TCGA-BH-A0AU-11A_7f667d91-04aa-48e8-b675-9d99b64b2058 014_Tex_BRCA_TCGA-BH-A0AU-01A_e7a641f3-cc31-4319-a04b-75c42e991711 014_Ttr_BRCA_TCGA-BH-A0AU-01A_23e09239-bfc3-4c2e-b690-db940d5292f7 15 015_Nex_BRCA_TCGA-BH-A18S-11A_9e6d6a2d-ce9e-4d44-9603-f843ffa06c63 0.8948 0.89 NaN 0.85 0.8676 015_Ntr_BRCA_TCGA-BH-A18S-11A_b54a0f88-21be-4c6d-a27a-1c1b8959652c 015_Tex_BRCA_TCGA-BH-A18S-01A_d4746397-9268-460a-954b-e5b5921138f9 015_Ttr_BRCA_TCGA-BH-A18S-01A_e0a3ea3a-ffce-4e30-9f42-cb047a7644a1 016_Nex_BRCA_TCGA-BH-A0HK-11A_d256dce0-d74b-4f8f-bf47-40b1b953fc7f 0.7649 0.78 0.9163 0.925 0.8357 016_Ntr_BRCA_TCGA-BH-A0HK-11A_438650e8-0ee2-4c74-8432-88b5c8006187 016_Tex_BRCA_TCGA-BH-A0HK-01A_944b4c29-bf72-4eec-b277-badc237730de 016_Ttr_BRCA_TCGA-BH-A0HK-01A_fe04f368-0a73-4f97-9d6b-2986f9b2b052 17 017_Nex_BRCA_TCGA-A7-A0D9-11A_dda70534-0d4d-4c30-9c6a-fb3c39396fb0 0.8911 0.8 1 0.775 0.8921 017_Ntr_BRCA_TCGA-A7-A0D9-11A_17cf6364-e228-4ee9-bffa-d1ad75f4152b 017_Tex_BRCA_TCGA-A7-A0D9-01A_821d7a33-77fb-496e-be9c-0552b12cbbee 017_Ttr_BRCA_TCGA-A7-A0D9-01A_c0ecd314-9d99-48ec-83f1-5a0c1ed656aa 18 018_Nex_BRCA_TCGA-BH-A0BV-11A_56dfc492-2b1f-4494-9ba9-14a70601ae21 0.6895 0.54 NaN 0.725 0.6749 018_Ntr_BRCA_TCGA-BH-A0BV-11A_20459115-d7be-4d04-896f-c5ff6923ec4c 018_Tex_BRCA_TCGA-BH-A0BV-01A_beb9e4cf-1f76-4a26-acee-e88d0936e60b 018_Ttr_BRCA_TCGA-BH-A0BV-01A_d037d3c2-e316-473d-9970-d4fb43615d95 19 019_Nex_BRCA_TCGA-E2-A1LH-11A_61558dd3-8f6c-4f70-8717-7676580fa5a7 0.5948 0.32 0.5637 0.8 0.4633 019_Ntr_BRCA_TCGA-E2-A1LH-11A_c7e02b93-465f-47da-81d7-ec9a8cb1e52b 019_Tex_BRCA_TCGA-E2-A1LH-01A_f54770bb-5dd0-48cf-ac5a-3f023a6aef95 019_Ttr_BRCA_TCGA-E2-A1LH-01A_169c390c-a211-4db0-a983-9bf5d6eee16e 20 020_Nex_BRCA_TCGA-BH-A0DD-11A_e9fe9b97-f7c7-40dc-ae31-17bb15c9fd8b 0.8677 0.79 0.9459 0.625 0.8714 020_Ntr_BRCA_TCGA-BH-A0DD-11A_5482cdd0-3698-455b-97c1-b10c69d67ae9 020_Tex_BRCA_TCGA-BH-A0DD-01A_99ca9706-f2bf-430b-9b23-e0947c0f8593 020_Ttr_BRCA_TCGA-BH-A0DD-01A_90cbc532-1ca8-46d6-977c-72b6d01e9c34
024_Nex_BRCA_TCGA-BH-A0AZ-11A_9bbae9a0-9f12-48cf-9aa7-d070c6627ea5 0.6505 0.53 0.8696 0.7 0.6655 024_Ntr_BRCA_TCGA-BH-A0AZ-11A_693bf8e4-b266-4b58-b812-f579179efb65 024_Tex_BRCA_TCGA-BH-A0AZ-01A_664528b7-b511-4627-8464-0702263434c5 024_Ttr_BRCA_TCGA-BH-A0AZ-01A_07f377f4-0bd1-4647-bf06-ff6ed553c44a 25 025_Nex_BRCA_TCGA-BH-A0HA-11A_c61bb1ab-688f-4d58-8388-60ae77c28840 0.6418 0.74 0.9258 0.725 0.7386 025_Ntr_BRCA_TCGA-BH-A0HA-11A_09e07a68-a443-4c16-a0de-78cd8aea59c0 025_Tex_BRCA_TCGA-BH-A0HA-01A_2c144eba-6490-4d64-9446-085d6edc8308 025_Ttr_BRCA_TCGA-BH-A0HA-01A_6d483def-2d91-4afc-991a-4a29804a6f3a 26 026_Nex_BRCA_TCGA-A7-A0CE-11A_eee8d4d0-d524-47f5-b076-6ad6216de1a3 0.9035 0.73 NaN 0.835 0.8551 026_Ntr_BRCA_TCGA-A7-A0CE-11A_548cad87-ec95-47e2-890e-7c8284ea5b88 026_Tex_BRCA_TCGA-A7-A0CE-01A_4288da4e-7e77-434b-a092-9450b0cb7833 026_Ttr_BRCA_TCGA-A7-A0CE-01A_14201682-0c8d-49c7-a5e1-7026e1a07b69 27 027_Nex_BRCA_TCGA-BH-A0DK-11A_3f4400a1-84ab-4198-b9a1-67b2ffc5ef36 0.5384 0.53 0.7316 0.7 0.6837 027_Ntr_BRCA_TCGA-BH-A0DK-11A_ae67044f-62c9-405f-bfc1-f0b8f1bc66d3 027_Tex_BRCA_TCGA-BH-A0DK-01A_e3e2053a-3ca2-4527-9b94-209def68dcc3 027_Ttr_BRCA_TCGA-BH-A0DK-01A_a3df35ec-a8d2-44ad-8ba6-eaba504261e0 28 028_Nex_BRCA_TCGA-BH-A0E1-11A_f6fed4ed-a853-40aa-bf7b-e627efd402d6 0.8676 0.75 0.9742 0.825 0.8524 028_Ntr_BRCA_TCGA-BH-A0E1-11A_52441de4-e26b-42b3-b061-94907c049501 028_Tex_BRCA_TCGA-BH-A0E1-01A_3c7e6a59-08b8-4903-932a-99946a96b746 028_Ttr_BRCA_TCGA-BH-A0E1-01A_f412f8d8-9e35-41d9-b44a-131186cb4bb0 29 029_Nex_BRCA_TCGA-BH-A0DG-11A_c99b1fb3-17e3-4472-86ee-7fda358a92c2 0.6358 0.42 0.7804 0.775 0.5386 029_Ntr_BRCA_TCGA-BH-A0DG-11A_bfdaf242-1e97-450d-9983-2cbb4e99305d 029_Tex_BRCA_TCGA-BH-A0DG-01A_721e2f71-60ae-4d63-9f05-113bce56c672 029_Ttr_BRCA_TCGA-BH-A0DG-01A_865afd6b-84a7-4dde-aa23-0b925c0b9d50 30 030_Nex_BRCA_TCGA-AC-A2FB-11A_552279ea-d7b1-496d-8170-ca30f5b62b5a 0.5372 0.23 0.5493 0.7 0.4436 030_Ntr_BRCA_TCGA-AC-A2FB-11A_56cd7da0-2c47-4986-91ce-07db2bb87369 030_Tex_BRCA_TCGA-AC-A2FB-01A_de000c35-8bf4-470a-9656-1b5da0deebe6 030_Ttr_BRCA_TCGA-AC-A2FB-01A_35aa5078-e07f-4a0f-84c1-01a0e566e97c 031_Nex_BRCA_TCGA-BH-A0H7-11A_abfca562-d328-40d2-83bb-e584123b0f28 0.7939 0.63 0.9561 0.725 0.7534 031_Ntr_BRCA_TCGA-BH-A0H7-11A_d969d9b2-9d8b-4594-95d4-87e6ce1236fc 031_Tex_BRCA_TCGA-BH-A0H7-01A_e8daad78-39fc-4835-b1c4-8807653d9c9a 031_Ttr_BRCA_TCGA-BH-A0H7-01A_0d37f87a-760a-472a-acba-bbc255422fbe 32 032_Nex_BRCA_TCGA-BH-A1EU-11A_38e87966-9605-4454-a4d1-28f96b7689f7 0.5387 0.33 0.6869 0.65 0.4299 032_Ntr_BRCA_TCGA-BH-A1EU-11A_3b00c121-17f2-461e-8873-08d15c9ec9f4 032_Tex_BRCA_TCGA-BH-A1EU-01A_4bccbb0f-2641-44df-b89a-42f020b4c08f 032_Ttr_BRCA_TCGA-BH-A1EU-01A_86e3dba1-48fb-44cc-b046-8bc35963ce99 33 033_Nex_BRCA_TCGA-BH-A0DP-11A_27543260-52ac-444b-8214-e62dca2cc8fe 0.7037 0.42 0.8565 0.7 0.655 033_Ntr_BRCA_TCGA-BH-A0DP-11A_30f4e5d8-a13d-4ef2-88e0-a01e07c2e142 033_Tex_BRCA_TCGA-BH-A0DP-01A_0326975a-2e56-404a-8776-92c5c5678853 033_Ttr_BRCA_TCGA-BH-A0DP-01A_7ff8a7a0-5235-4de0-bb9f-b811230b5bda 34 034_Nex_BRCA_TCGA-BH-A18N-11A_6c8aae77-5f43-41ec-a139-81f3ba02f6ea 0.8685 0.76 NaN 0.9 0.832 034_Ntr_BRCA_TCGA-BH-A18N-11A_0738f1b2-aa50-4921-82e1-d3614b40f98d 034_Tex_BRCA_TCGA-BH-A18N-01A_b6f89799-9070-4fbc-b10c-53cbe515eccc 034_Ttr_BRCA_TCGA-BH-A18N-01A_4b7b8eb8-d939-411c-be5e-cf41a5521963 35 035_Nex_BRCA_TCGA-BH-A0BC-11A_6359db46-f8dd-4dc8-a3a9-8725d8f6958a 0.6221 0.6 0.8221 0.8 0.7727 035_Ntr_BRCA_TCGA-BH-A0BC-11A_2cb50d4a-d6df-4b64-acfb-7a7db5ddd1de 035_Tex_BRCA_TCGA-BH-A0BC-01A_73b9208d-336c-4990-a27d-0164a77dd165 035_Ttr_BRCA_TCGA-BH-A0BC-01A_92e26b53-f540-428a-a3c5-848a36b31171 36
036_Nex_BRCA_TCGA-BH-A0BZ-11A_2b4e3d99-07cd-4b06-ad97-82a19ac0eb5d 0.5788 0.37 0.7363 0.6 0.5138 036_Ntr_BRCA_TCGA-BH-A0BZ-11A_3aa16a4b-4e35-4530-84fb-0cb204290b08 036_Tex_BRCA_TCGA-BH-A0BZ-01A_74414845-839f-4885-b13d-3f2e17781f84 036_Ttr_BRCA_TCGA-BH-A0BZ-01A_efefcc2f-72e9-4634-b943-d26083e1a312 37
037_Nex_BRCA_TCGA-BH-A0DL-11A_2d495f9c-4ffa-4169-b583-6786612e9606 0.6944 0.53 NaN 0.65 0.6655 037_Ntr_BRCA_TCGA-BH-A0DL-11A_bd8b100a-8391-4046-847f-c3fdd3830eeb 037_Tex_BRCA_TCGA-BH-A0DL-01A_dfd355e4-478a-47cb-9aab-8ce22b6f936c 037_Ttr_BRCA_TCGA-BH-A0DL-01A_11d77ef2-b3f9-4af9-8490-71f9a8c599e0 38 038_Nex_BRCA_TCGA-BH-A0BT-11A_32430467-5215-4738-86a3-5bbe11fbba86 0.8096 0.67 0.9054 0.75 0.7751 038_Ntr_BRCA_TCGA-BH-A0BT-11A_cbef4196-5f3b-40d9-b26f-5b2bb82fbe9b 038_Tex_BRCA_TCGA-BH-A0BT-01A_e78b9962-7bc2-4238-806a-5933ac07de99 038_Ttr_BRCA_TCGA-BH-A0BT-01A_aae75165-efa0-46b3-8a8d-82dc7d82aecd 39 039_Nex_BRCA_TCGA-BH-A18Q-11A_b58d4f69-a4ea-489b-9d25-e5cfdc465adb 0.8117 0.73 NaN 0.9 0.836 039_Ntr_BRCA_TCGA-BH-A18Q-11A_76575097-374b-4fb2-8054-2a31b4204165 039_Tex_BRCA_TCGA-BH-A18Q-01A_1f2c90ef-a05d-494c-9232-e705691f46b9 039_Ttr_BRCA_TCGA-BH-A18Q-01A_f0173e28-7fe4-411f-a187-57fd94a7935a 40 040_Nex_BRCA_TCGA-E2-A1LB-11A_e2d7a695-b0bf-4432-8f98-1843bb49efba 0.8415 0.68 0.8192 0.9 0.815 040_Ntr_BRCA_TCGA-E2-A1LB-11A_6eb518ab-f174-45ae-8d65-74086ecb1125 040_Tex_BRCA_TCGA-E2-A1LB-01A_3ddbc444-ee1b-43be-bab5-b0f67d5eb339 040_Ttr_BRCA_TCGA-E2-A1LB-01A_d7d566a0-b6d0-4a4f-8211-9309b27b0ade 41 041_Nex_BRCA_TCGA-BH-A0DH-11A_a7a7e0f6-100f-4145-9599-693e6c14e903 0.8317 0.76 0.8955 0.85 0.8597 041_Ntr_BRCA_TCGA-BH-A0DH-11A_5a0374e5-cee9-4952-9df0-4ff125196478 041_Tex_BRCA_TCGA-BH-A0DH-01A_eb680f8c-4ba1-45ef-8b94-e58b68922f2f 041_Ttr_BRCA_TCGA-BH-A0DH-01A_71a3c27c-0982-4da6-b260-cf16a4868a19 42 042_Nex_BRCA_TCGA-BH-A0B7-11A_d9aca915-ea30-4939-af59-edaef8872396 0.6207 0.2 NaN 0.575 0.4954 042_Ntr_BRCA_TCGA-BH-A0B7-11A_8db8b247-05b8-46ca-8791-ecf846da2c7f 042_Tex_BRCA_TCGA-BH-A0B7-01A_e3b9eb8a-93f3-4668-a54b-fa8b15be5667 042_Ttr_BRCA_TCGA-BH-A0B7-01A_0fdae4ee-ca68-4ba4-ba58-76058409b02f 43 043_Nex_BRCA_TCGA-E2-A15I-11A_36024763-f828-4496-8fdc-46d5c3de569b 0.7689 0.62 0.768 0.8 0.7565 043_Ntr_BRCA_TCGA-E2-A15I-11A_ffa9ace8-9253-4775-9ad2-2a8a50c0f9c9 043_Tex_BRCA_TCGA-E2-A15I-01A_8c627466-eb99-4a7e-87e6-314ae8ed32a1 043_Ttr_BRCA_TCGA-E2-A15I-01A_3a4e3785-fb2e-4ffc-9644-91c78a9a9ebe 44 044_Nex_BRCA_TCGA-BH-A0DV-11A_79a92eab-c87c-4209-819e-193d653c0df6 0.6021 0.31 0.7631 0.7 0.4856 044_Ntr_BRCA_TCGA-BH-A0DV-11A_e87e7e3e-9059-47cf-9f45-8959250b037f 044_Tex_BRCA_TCGA-BH-A0DV-01A_105290eb-b626-4318-9b8a-42f477e2cec6 044_Ttr_BRCA_TCGA-BH-A0DV-01A_7bad3f4c-6065-4245-8119-c25596f38829 45 045_Nex_BRCA_TCGA-BH-A0DZ-11A_aebf04d4-4a1b-4a50-b5f1-0f9e2c273121 0.6572 0.65 NaN 0.885 0.7792 045_Ntr_BRCA_TCGA-BH-A0DZ-11A_80b4d43d-9e7d-4ab8-b05a-0eb51faa9d12 045_Tex_BRCA_TCGA-BH-A0DZ-01A_4e7d62f5-4be9-4b9c-9b7c-aec4567dded2 045_Ttr_BRCA_TCGA-BH-A0DZ-01A_8b1982a0-315c-47e1-8de0-a1e5ec51dd74 46 046_Nex_BRCA_TCGA-BH-A18R-11A_b32b2067-a79e-42c5-ae78-135c845253fe 0.8685 0.53 NaN 0.85 0.7466 046_Ntr_BRCA_TCGA-BH-A18R-11A_f82099ae-9d74-44d8-ba5b-cd10eeb09807 046_Tex_BRCA_TCGA-BH-A18R-01A_c518bc34-50dc-4265-824f-a954e4d19f0b 046_Ttr_BRCA_TCGA-BH-A18R-01A_fc65ff2e-9808-4c1e-a16b-8285fd0d27df 47 047_Nex_BRCA_TCGA-E2-A15K-11A_6299f114-932a-42c0-8cab-bebb12c996fc 0.7425 0.7 0.724 0.9 NaN 047_Ntr_BRCA_TCGA-E2-A15K-11A_c2ab9488-d9a4-479c-b9e2-6f9b0cdbaacb 047_Tex_BRCA_TCGA-E2-A15K-01A_80019ec7-b0d8-4573-b5d6-a5d9f2745ab2 047_Ttr_BRCA_TCGA-E2-A15K-01A_7e3a600b-edd8-428e-b88d-af4c63dcaad9 48 048_Nex_BRCA_TCGA-BH-A1EN-11A_a6259119-3d8a-4749-a517-c675efbc8215 0.8518 0.7 0.9612 0.85 0.8179 048_Ntr_BRCA_TCGA-BH-A1EN-11A_488f1b69-c2a3-429b-a972-31edfd615a67 048_Tex_BRCA_TCGA-BH-A1EN-01A_72e4cb26-911c-4804-9e4f-ed5b51024cd1 048_Ttr_BRCA_TCGA-BH-A1EN-01A_96360e75-26b6-4647-b974-9e31ae6de00c 49 049_Nex_BRCA_TCGA-BH-A0H9-11A_d8b452e5-010a-4fec-80a4-770a5a492090 0.8872 0.35 0.7934 0.7 0.747 049_Ntr_BRCA_TCGA-BH-A0H9-11A_1337ceba-db77-4b31-ac20-1c6a8bb5f546 049_Tex_BRCA_TCGA-BH-A0H9-01A_ac4899fe-f56d-4b98-9a54-73ffd0c90652 049_Ttr_BRCA_TCGA-BH-A0H9-01A_a97d281f-235f-481b-b26b-169b96e0e65f 50 050_Nex_BRCA_TCGA-E2-A153-11A_1c3f2e11-952a-4e47-a8b9-25f4fe4bf205 0.6589 0.61 NaN 0.6 0.5474 050_Ntr_BRCA_TCGA-E2-A153-11A_bd0ab51c-c114-40e3-a6a1-4b8f576a41d3 050_Tex_BRCA_TCGA-E2-A153-01A_85258fb2-26ab-4a66-b8a5-5a58bf9275e0 050_Ttr_BRCA_TCGA-E2-A153-01A_091a54cd-e3b3-4af2-828f-a80e64504f5e 51 051_Nex_BRCA_TCGA-BH-A0BW-11A_ab130f7f-4070-436e-ac7b-c1b7aecb9dc6 0.6784 0.54 NaN 0.6 0.6749 051_Ntr_BRCA_TCGA-BH-A0BW-11A_2581c95b-1b57-4407-bbc4-a65c89bfd136 051_Tex_BRCA_TCGA-BH-A0BW-01A_7661179f-df6c-4a57-adca-224b62d98348 051_Ttr_BRCA_TCGA-BH-A0BW-01A_a15d171e-ac82-4712-94a9-b4799e7b2915 52 052_Nex_BRCA_TCGA-BH-A18J-11A_3aa5b173-17b2-425f-b5c7-395614d6bfa2 0.8066 0.51 NaN 0.7 0.7243 052_Ntr_BRCA_TCGA-BH-A18J-11A_307eb339-a781-45cc-9597-da0be7e5438a 052_Tex_BRCA_TCGA-BH-A18J-01A_f639a485-8ebb-4dcc-9f2e-a8d7ad05564f 052_Ttr_BRCA_TCGA-BH-A18J-01A_0e985713-0492-4191-918b-fef6c23389b1 53 053_Nex_BRCA_TCGA-BH-A204-11A_98e5c1d8-5c14-4416-8437-31d0098dd341 0.8763 0.89 0.9364 0.85 0.9601 053_Ntr_BRCA_TCGA-BH-A204-11A_2afdc0cf-2723-42dd-89f7-fa03c6ba218c 053_Tex_BRCA_TCGA-BH-A204-01A_970600ce-9486-4641-8555-533132f7a414 053_Ttr_BRCA_TCGA-BH-A204-01A_893fcf87-8baa-424e-8866-bcf8cfa26cf9 54 054_Nex_BRCA_TCGA-BH-A18K-11A_502ee86f-829e-4b6e-a8f1-be082c445310 0.8058 0.58 NaN 0.8 0.7468 054_Ntr_BRCA_TCGA-BH-A18K-11A_375bcdd8-8628-4047-948a-fa98bfa3dba5 054_Tex_BRCA_TCGA-BH-A18K-01A_7e8c2ea7-04ce-47c5-b848-229f96563015 054_Ttr_BRCA_TCGA-BH-A18K-01A_12473f59-359c-4306-ade3-2156e458cd05 55 055_Nex_BRCA_TCGA-BH-A0C3-11A_9fedd2f4-d2c8-4d24-987b-69edf55e15f1 0.6289 0.39 0.7847 0.45 0.528 055_Ntr_BRCA_TCGA-BH-A0C3-11A_a49fa48d-efc4-4b99-a42e-7019236af6c8 055_Tex_BRCA_TCGA-BH-A0C3-01A_866d9cb0-a299-46c1-a787-2e73fd758fbe 055_Ttr_BRCA_TCGA-BH-A0C3-01A_164f86df-dec9-44ef-b1c7-2ee5d33617be 56 056_Nex_BRCA_TCGA-BH-A0C0-11A_9778035c-19ff-4a89-bba2-fa83e51d9add 0.6223 0.27 0.5586 0.85 0.5068 056_Ntr_BRCA_TCGA-BH-A0C0-11A_52a72824-0b41-4b8e-86f0-41ee5e00c989 056_Tex_BRCA_TCGA-BH-A0C0-01A_568a2363-b7e5-48f6-9242-328950eebf39 056_Ttr_BRCA_TCGA-BH-A0C0-01A_f5fe9655-f5b4-413b-882c-43b872e4ec23 57 057_Nex_BRCA_TCGA-BH-A0E0-11A_59fa57c8-7435-4499-bd09-bf969596c18d 0.9013 0.57 0.7391 0.875 0.7486 057_Ntr_BRCA_TCGA-BH-A0E0-11A_a3e5f7bd-3ab0-4ea6-9de1-742de1a2ed78 057_Tex_BRCA_TCGA-BH-A0E0-01A_72436fcd-21fd-46bd-bd36-7f514edb51de 057_Ttr_BRCA_TCGA-BH-A0E0-01A_b98d2a16-974c-4728-9648-81dc4314f225 58 058_Nex_BRCA_TCGA-BH-A18M-11A_8e0cb775-9fc9-4001-973c-ef6cec2a38b6 0.7363 0.45 NaN 0.85 0.6525 058_Ntr_BRCA_TCGA-BH-A18M-11A_3e02aa37-30ee-4663-bba1-280e5127f302 058_Tex_BRCA_TCGA-BH-A18M-01A_69ccc418-264c-4e8e-a034-39607c07fa59 058_Ttr_BRCA_TCGA-BH-A18M-01A_aea8fff8-dbc9-4a1b-9a3a-ca1882432c57 59 059_Nex_BRCA_TCGA-E2-A1BC-11A_45b8b995-c477-4358-8050-6d41c267b467 0.8083 0.56 0.8676 0.85 0.7707 059_Ntr_BRCA_TCGA-E2-A1BC-11A_205007dd-4bc1-4e1f-9fdb-115b0e7c9836 059_Tex_BRCA_TCGA-E2-A1BC-01A_f969cce4-0fcd-47bb-91f1-37ba0f314994 059_Ttr_BRCA_TCGA-E2-A1BC-01A_ea3bd91d-520b-4198-b011-a0f578eadc3e 60 060_Nex_BRCA_TCGA-BH-A203-11A_f08939ed-a218-4688-b419-a91333d0267b 0.7637 0.37 0.6872 0.75 0.5905 060_Ntr_BRCA_TCGA-BH-A203-11A_8c2d82aa-0b36-488f-8cf1-f82795b831c5 060_Tex_BRCA_TCGA-BH-A203-01A_55a9b84d-ca9f-402c-8d93-15aef2fde988 060_Ttr_BRCA_TCGA-BH-A203-01A_8986bdd8-2be5-41ed-9596-59ca1f95e1c0 61 061_Nex_BRCA_TCGA-BH-A1F2-11A_d6eb2d94-1234-46b3-9403-958f3b340fd0 0.7507 0.52 0.8661 0.6 0.754 061_Ntr_BRCA_TCGA-BH-A1F2-11A_210014fa-f161-4799-a1c0-6f93d4b631f6 061_Tex_BRCA_TCGA-BH-A1F2-01A_91aeda5a-ed5a-4175-b19e-408219b980fc 061_Ttr_BRCA_TCGA-BH-A1F2-01A_ceb5a503-e107-4721-9283-714406cdd914 062_Nex_BRCA_TCGA-BH-A1EO-11A_90308930-e3c5-47bb-bcee-58eaae7d3dfa 0.5849 0.48 0.8854 0.9 0.7493 062_Ntr_BRCA_TCGA-BH-A1EO-11A_a426d9c2-86b1-4db1-b49c-eceaa01273a9 062_Tex_BRCA_TCGA-BH-A1EO-01A_7787e3e2-f604-4b4d-a3bc-60c795d4177b 062_Ttr_BRCA_TCGA-BH-A1EO-01A_e31bd4a4-ecda-49b4-83b0-7f1496c2f9ae 63 063_Nex_BRCA_TCGA-BH-A18V-11A_353e7fa1-08c5-400a-b352-b5325e40d66c 0.6941 0.56 NaN 0.75 NaN 063_Ntr_BRCA_TCGA-BH-A18V-11A_e3c5cba8-e3ba-4e0b-929b-280708e0a855 063_Tex_BRCA_TCGA-BH-A18V-01A_abcf2a8e-6f4c-4668-9ef9-41d95d16e8e6 063_Ttr_BRCA_TCGA-BH-A18V-01A_286394db-7d5e-4de2-b386-581352164350 64 064_Nex_BRCA_TCGA-BH-A0DT-11A_6dde640a-1d79-4e7d-9491-c500b8183d9a 0.7462 0.42 NaN 0.55 0.6659 064_Ntr_BRCA_TCGA-BH-A0DT-11A_71aa4cd6-75ea-4e10-b16c-ea9adbf31a98 064_Tex_BRCA_TCGA-BH-A0DT-01A_9d93c6fb-336a-4cb4-9f33-8557456753b1 064_Ttr_BRCA_TCGA-BH-A0DT-01A_61ad7408-dacd-4913-a479-c456e8b03191 65 065_Nex_BRCA_TCGA-GI-A2C9-11A_454dbdba-da53-4e99-9670-dff1e5bbb77c 0.8062 0.51 0.8386 0.8 0.6969 065_Ntr_BRCA_TCGA-GI-A2C9-11A_d8aa0349-d74e-4891-8398-6476eb1935f0 065_Tex_BRCA_TCGA-GI-A2C9-01A_2f2b0909-488b-4fa3-8251-2ef6e7d5869e 065_Ttr_BRCA_TCGA-GI-A2C9-01A_01ea694e-989b-4a35-9397-5e508656d1d8 66 066_Nex_BRCA_TCGA-BH-A209-11A_c580c610-832d-45be-9963-06bb918ede73 0.5979 0.24 0.6243 0.6 0.4645 066_Ntr_BRCA_TCGA-BH-A209-11A_b8b48554-ca2f-466d-85b0-9d473cca8ca7 066_Tex_BRCA_TCGA-BH-A209-01A_7b85ca36-2fe9-4156-99eb-f79463dbc572 066_Ttr_BRCA_TCGA-BH-A209-01A_b2cf947a-5ed1-4e24-8752-bf2a6eca895a 67 067_Nex_BRCA_TCGA-BH-A1EV-11A_f4d30842-7873-46d3-8f25-ae7d05909175 0.8435 0.61 0.9517 0.8 0.817 067_Ntr_BRCA_TCGA-BH-A1EV-11A_73e296db-9eec-4060-97c9-80a98dbb9fb6 067_Tex_BRCA_TCGA-BH-A1EV-01A_fb502696-cb13-487a-a70a-6ceefcf20ca0 067_Ttr_BRCA_TCGA-BH-A1EV-01A_93ab3adf-7ab9-455e-9007-9f51443352fe 68 068_Nex_BRCA_TCGA-GI-A2C8-11A_836e4482-11c7-4422-a2e5-cac9b846ea71 0.601 0.48 0.7846 0.85 0.6998 068_Ntr_BRCA_TCGA-GI-A2C8-11A_580d9a3d-e198-4e7b-aa1f-419d868bb0b5 068_Tex_BRCA_TCGA-GI-A2C8-01A_146c0ba4-6761-446c-be7c-7e56c0ffa37b 068_Ttr_BRCA_TCGA-GI-A2C8-01A_c0ee6e25-02b9-4b2f-9f23-fd61eedf9945 69 069_Nex_BRCA_TCGA-BH-A0BM-11A_92faafbd-6a76-4116-80fc-a15767aa81d0 0.796 0.61 0.9189 0.84 0.7886 069_Ntr_BRCA_TCGA-BH-A0BM-11A_ae127be2-5e4c-4b7e-9cf8-3aa9e529baaa 069_Tex_BRCA_TCGA-BH-A0BM-01A_c513ed81-255f-43b0-b8aa-984326201745 069_Ttr_BRCA_TCGA-BH-A0BM-01A_006b2b95-7069-4cb6-bfe8-7edb80056add 70 070_Nex_BRCA_TCGA-BH-A18L-11A_7a010ccd-f780-45f0-98da-cc738e87b6d3 0.927 0.81 NaN 0.8 0.9113 070_Ntr_BRCA_TCGA-BH-A18L-11A_ef4660c0-c177-4d46-90f9-56e3dc47b59e 070_Tex_BRCA_TCGA-BH-A18L-01A_0d4aca9c-c11e-4f78-a250-08d45ce4828e 070_Ttr_BRCA_TCGA-BH-A18L-01A_1af43803-7afa-4d2b-aa78-2dec84c1e702 71 071_Nex_BRCA_TCGA-A7-A13F-11A_471d1e10-7c79-44f9-a373-bd3e510b6155 0.8478 0.65 0.9236 0.7 0.7915 071_Ntr_BRCA_TCGA-A7-A13F-11A_4e4cd9e5-27bb-4ea7-9328-0b267373ec1c 071_Tex_BRCA_TCGA-A7-A13F-01A_d8fad6b2-66b8-4d6f-b018-653998675921 071_Ttr_BRCA_TCGA-A7-A13F-01A_75898a6d-75e4-4dca-a7ed-c11056e0c9c4 72 072_Nex_BRCA_TCGA-E2-A15M-11A_b2138cda-519f-4691-bf1c-0f863b55d888 0.4911 0.28 NaN 0.8 0.4285 072_Ntr_BRCA_TCGA-E2-A15M-11A_bf873756-8ee8-49bd-b2ca-17223c7ef962 072_Tex_BRCA_TCGA-E2-A15M-01A_1ccf392d-7959-4bb9-8ca8-4298409f4951 072_Ttr_BRCA_TCGA-E2-A15M-01A_b2569032-6147-4a1c-973f-d5985127e9f4
